This also highlights the regional inequity of guidance for use of isCGM in diabetes, since the Health Technology Wales guidance for use of isCGM in management of T1D or T2D mandates its use for all persons with diabetes on any insulin therapy, not just MDI, and does not include any qualifying statements regarding risks for hypoglycaemia.29 This evidence concerns the gene INS and type 1 diabetes mellitus.